Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

Delayed Quote. Delayed  - 05/30 05:35:13 pm
49.94 EUR   -1.50%
05/24 MORPHOSYS : and MD Anderson Cancer Center Join Forces for the Develo..
05/24 MORPHOSYS : and MD Anderson Cancer Center Join Forces for the Develo..
05/19 MORPHOSYS : to Present Clinical Trial Data on Proprietary Programs a..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
05/24/2016 05/25/2016 05/26/2016 05/27/2016 05/30/2016 Date
49.495(c) 49.8(c) 49.985(c) 50.7(c) 49.94(c) Last
120 568 88 306 53 851 72 063 58 977 Volume
+4.36% +0.62% +0.37% +1.43% -1.50% Change
More quotes
Financials (€)
Sales 2016 48,9 M
EBIT 2016 -64,4 M
Net income 2016 -45,4 M
Finance 2016 215 M
Yield 2016 -
Sales 2017 63,4 M
EBIT 2017 -44,3 M
Net income 2017 -33,3 M
Finance 2017 199 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 23,1x
EV / Sales 2017 18,1x
Capitalization 1 345 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
Sector
Biotechnology & Medical Research
Calendar
06/02 | 04:00amShareholder meeting
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
05/24 MORPHOSYS : and MD Anderson Cancer Center Join Forces for the Development of Nov..
05/24 MORPHOSYS : and MD Anderson Cancer Center Join Forces for the Development of Nov..
05/19 MORPHOSYS : to Present Clinical Trial Data on Proprietary Programs at Upcoming A..
05/19 MORPHOSYS : to Present Clinical Trial Data on Proprietary Programs at Upcoming A..
05/04 MORPHOSYS : to Present at Three Upcoming Conferences
05/03 MORPHOSYS : AG Reports Results for the First Three Months of 2016
04/27 MORPHOSYS : to Host Q1 2016 Conference Call on May 3, 2016
04/21 MORPHOSYS AG : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RE..
04/21 AD HOC : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIEN..
04/20 MORPHOSYS : Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) ..
More news
Sector news : Biotechnology & Medical Research - NEC
11:01a Genmab Achieves USD 30 Million Milestone in DARZALEX(r) (daratumumab) Collabo..
10:57a GENMAB A/S : Achieves USD 30 Million Milestone in DARZALEX® (daratumumab) Collab..
03:07a Samsung Bioepis receives final European approval for its Remicade copy
05/27 AMGEN : receives positive CHMP opinion to extend indication of Kyprolis
05/27 Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Pos..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/03 MorphoSys' (MPSYF) CEO Simon Moroney on Q1 2016 Results - Earnings Call Trans..
05/03 MorphoSys AG reports Q1 results
03/11 Upcoming Events - Pivotal Data For Novartis And Perhaps Aduro Too
03/02 MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2015 Results - Earnings Call Trans..
03/02 MorphoSys AG reports Q4 results
Advertisement
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions